Evidence mapPaperPMID 41368766Full record

ReviewClinical pharmacology and therapeutics2026

Cardiovascular-Kidney-Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology.

Aaron S Devanathan, Thomas D Nolin

Abstract readReview
In one paragraph

Review in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aaron S DevanathanDepartment of Pharmacy & Therapeutics, Center for Clinical Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-2778-3725
Thomas D NolinDepartment of Pharmacy & Therapeutics, Center for Clinical Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-4339-1382

Funding

Multiomics and Antiretroviral Drug Exposure for assessing Metabolic Effects (MADE-FOR-ME)DP1HL174180 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2025 to 2025
$522k
NHLBI NIH HHS DP1 HL174180NIH HHS DP1HL174180
6 · The paper itself

Abstract

As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular-Kidney-Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART-associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby heightening the risk of drug-drug interactions and adverse drug effects. Therefore, CKM in PWH represents an emerging clinical pharmacology priority. We outline gaps and challenges and call for CKM research in PWH.

Indexed as

Anti-HIV AgentsCardiovascular DiseasesHIV InfectionsMetabolic SyndromeDrug InteractionsHumansPharmacology, ClinicalAnti-HIV Agents

Identifiers

PMID41368766
PMCPMC12698119

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.